Why Is PDS Biotechnology Stock Gaining Wednesday?

Benzinga_recent_news04-16

The published data from the trial indicate that PDS01ADC significantly enhances immune response in colorectal cancer patients who have failed prior treatments. The stock’s rise follows the publication...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627316822?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/15/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-04-16 01:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627316822","market":"sh","top_or_hot":-1,"title":"Why Is PDS Biotechnology Stock Gaining Wednesday?","media":"Benzinga_recent_news","content":"<div>\n<p>The published data from the trial indicate that PDS01ADC significantly enhances immune response in colorectal cancer patients who have failed prior treatments.\nThe stock’s rise follows the publication...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/04/51839004/why-is-pds-biotechnology-stock-gaining-wednesday\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is PDS Biotechnology Stock Gaining Wednesday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is PDS Biotechnology Stock Gaining Wednesday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-16 01:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/04/51839004/why-is-pds-biotechnology-stock-gaining-wednesday><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The published data from the trial indicate that PDS01ADC significantly enhances immune response in colorectal cancer patients who have failed prior treatments.\nThe stock’s rise follows the publication...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/04/51839004/why-is-pds-biotechnology-stock-gaining-wednesday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFS","symbol_name":"Provident Financial Services Inc","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/04/51839004/why-is-pds-biotechnology-stock-gaining-wednesday","article_id":"2627316822","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/15/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/04/51839004/why-is-pds-biotechnology-stock-gaining-wednesday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627316822","pubTimestamp":1776273240,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFS":"Provident Financial Services Inc","BK4195":"互助储蓄与抵押信贷金融服务","PDS":"Precision Drilling Corp","BK4211":"区域性银行","BK4092":"石油与天然气钻井"},"translate_title":"为什么PDS Biotechnology股票周三上涨？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFS":1,"PDS":1.5},"content_text":"The published data from the trial indicate that PDS01ADC significantly enhances immune response in colorectal cancer patients who have failed prior treatments.\nThe stock’s rise follows the publication of findings showing a 78% objective response rate with PDS01ADC versus 35% in a parallel trial without PDS01ADC.\nThis promising result comes from a study that included 22 patients, with a two-year survival rate exceeding 80% for those treated with PDS01ADC versus 35%.\nThe median progression-free survival (PFS) was not reached at the minimum follow-up of 13.1 months; in the parallel trial without PDS01ADC, the PFS was 8.1 months.\nEarlier, the company presented encouraging early results from an NCI-led trial investigating PDS01ADC at the AACR special conference on prostate cancer research.\nPDSB Stock Price Activity: PDS Biotechnology shares were up 25.47% at $1.33 at the time of publication on Wednesday, according to Benzinga Pro data.\nPhoto by Aunt Spray via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627316822","isCrawlerRequest":true}